[{"id":"930271d4-4c89-4b12-9340-38647392d747","acronym":"","url":"https://clinicaltrials.gov/study/NCT05732961","created_at":"2023-02-17T15:00:52.691Z","updated_at":"2025-02-25T14:17:40.080Z","phase":"Phase 2","brief_title":"Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms","source_id_and_acronym":"NCT05732961","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" SF3B1","pipe":" | ","alterations":" SF3B1 mutation","tags":["SF3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SF3B1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Reblozyl (luspatercept-aamt)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 02/21/2023","start_date":" 02/21/2023","primary_txt":" Primary completion: 06/20/2025","primary_completion_date":" 06/20/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-07"},{"id":"b4b55ef9-4653-42bf-95e0-84efd373e033","acronym":"","url":"https://clinicaltrials.gov/study/NCT05891249","created_at":"2023-06-06T14:07:08.438Z","updated_at":"2024-07-02T16:34:26.950Z","phase":"Phase 4","brief_title":"A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) \u0026 Beta-thalassemia (β-Thal) in India","source_id_and_acronym":"NCT05891249","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" SF3B1","pipe":" | ","alterations":" SF3B1 mutation","tags":["SF3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SF3B1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Reblozyl (luspatercept-aamt)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/05/2023","start_date":" 06/05/2023","primary_txt":" Primary completion: 04/13/2026","primary_completion_date":" 04/13/2026","study_txt":" Completion: 04/13/2026","study_completion_date":" 04/13/2026","last_update_posted":"2024-06-12"},{"id":"eecc0761-d3fa-49cf-82cd-389c0096a5df","acronym":"LUSPLUS","url":"https://clinicaltrials.gov/study/NCT05181592","created_at":"2022-01-06T22:53:42.390Z","updated_at":"2025-02-25T14:16:35.136Z","phase":"Phase 3","brief_title":"Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.","source_id_and_acronym":"NCT05181592 - LUSPLUS","lead_sponsor":"GWT-TUD GmbH","biomarkers":" SF3B1","pipe":" | ","alterations":" SF3B1 mutation • Chr del(5q)","tags":["SF3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SF3B1 mutation • Chr del(5q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Reblozyl (luspatercept-aamt)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 10/27/2021","start_date":" 10/27/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-10-12"},{"id":"5a55c8ba-84c1-4c67-a725-dab20754576f","acronym":"FISiM-Luspa","url":"https://clinicaltrials.gov/study/NCT05520749","created_at":"2022-08-30T20:55:51.039Z","updated_at":"2024-07-02T16:35:55.523Z","phase":"","brief_title":"Efficacy and Safety of Luspatercept: A Study by Fondazione Italiana Sindromi Mielodisplastiche","source_id_and_acronym":"NCT05520749 - FISiM-Luspa","lead_sponsor":"Fondazione Italiana Sindromi Mielodisplastiche-ETS","biomarkers":" SF3B1","pipe":" | ","alterations":" SF3B1 mutation","tags":["SF3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SF3B1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Reblozyl (luspatercept-aamt)"],"overall_status":"Completed","enrollment":" Enrollment 215","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 01/31/2023","study_completion_date":" 01/31/2023","last_update_posted":"2023-02-15"},{"id":"de27d4a7-da28-4adb-9c83-edc82f6ec299","acronym":"MEDALIST","url":"https://clinicaltrials.gov/study/NCT02631070","created_at":"2021-01-18T12:47:39.328Z","updated_at":"2025-02-25T16:15:32.760Z","phase":"Phase 3","brief_title":"A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes","source_id_and_acronym":"NCT02631070 - MEDALIST","lead_sponsor":"Celgene","biomarkers":" SF3B1","pipe":" | ","alterations":" SF3B1 mutation","tags":["SF3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SF3B1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Reblozyl (luspatercept-aamt)"],"overall_status":"Completed","enrollment":" Enrollment 229","initiation":"Initiation: 02/09/2016","start_date":" 02/09/2016","primary_txt":" Primary completion: 06/18/2019","primary_completion_date":" 06/18/2019","study_txt":" Completion: 11/26/2020","study_completion_date":" 11/26/2020","last_update_posted":"2021-12-17"}]